Loss of VHL in RCC reduces repair and alters cellular response to benzo[a]pyrene

Frontiers in Oncology

Volumn 3 OCT, Issue , 2013, Pages

  Schults, Marten A ^a   Oligschlaeger, Yvonne ^a   Godschalk, Roger W ^a   van Schooten, Frederik Jan ^a   Chiu, Roland K ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Carcinogens; Metabolism; Nucleotide excision repair; Renal cell carcinoma; Von Hippel Lindau

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BENZO [A] PYRENE; BENZO [A] PYRENE 7, 8 DIHYDRODIOL 9, 10 OXIDE; CARCINOGEN; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; DNA; EPOXIDE HYDROLASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 2B7; GLUTATHIONE TRANSFERASE P1; HYPOXIA INDUCIBLE FACTOR 1BETA; MESSENGER RNA; PHOSPHORUS 32; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP C PROTEIN;

ARTICLE; CARCINOGEN DNA INTERACTION; CELLULAR IMMUNITY; COMET ASSAY; CONTROLLED STUDY; DETOXIFICATION; EXCISION REPAIR; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE MUTATION; GENOMIC INSTABILITY; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; OXYGEN TENSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84891137388     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00270     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin (2010) 60:277-300. doi: 10.3322/caac.20073
2. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med (2005) 353:2477-90. doi:10.1056/NEJMra043172
3. Baldewijns MM, Van Vlodrop IJ, Vermeulen PB, Soetekouw PM, Van Engeland M, De Bruine AP. VHL and HIF signalling in renal cell carcinogenesis. J Pathol (2010) 221:125-38. doi:10.1002/path.2689
4. Nyhan MJ, O'Sullivan GC, Mckenna SL. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. Biochem Soc Trans (2008) 36:472-8. doi:10.1042/BST0360472
5. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (2001) 292:468-72. doi:10.1126/science.1059796
6. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem (2000) 275:25733-41. doi:10.1074/jbc.M002740200
7. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem (1999) 274:6519-25. doi:10.1074/jbc.274.10.6519
8. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A (1995) 92:5510-4. doi:10.1073/pnas.92.12.5510
9. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem (1996) 271:32529-37. doi:10.1074/jbc.271.51.32529
10. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol (2003) 1:E83. doi:10.1371/journal.pbio.0000083
11. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol (2005) 25:5675-86. doi:10.1128/MCB.25.13.5675-5686.2005
12. Wright TM, Rathmell WK. Identification of Ror2 as a hypoxia-inducible factor target in von Hippel-Lindau-associated renal cell carcinoma. J Biol Chem (2010) 285:12916-24. doi:10.1074/jbc.M109.073924
13. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res (1999) 59:5830-5.
14. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 399:271-5. doi:10.1038/20459
15. Kallio PJ, Pongratz I, Gradin K, Mcguire J, Poellinger L. Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci U S A (1997) 94:5667-72. doi:10.1073/pnas.94.11.5667
16. Reyes H, Reisz-Porszasz S, Hankinson O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science (1992) 256:1193-5. doi:10.1126/science.256.5060.1193
17. Gelboin HV. Benzo[alpha]pyrene metabolism, activation and carcinogenesis: role and regulation of mixed-function oxidases and related enzymes. Physiol Rev (1980) 60:1107-66.
18. Baird WM, Hooven LA, Mahadevan B. Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts and mechanism of action. Environ Mol Mutagen (2005) 45:106-14. doi:10.1002/em.20095
19. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene (2002) 21:7435-51. doi:10.1038/sj.onc.1205803
20. Schults MA, Timmermans L, Godschalk RW, Theys J, Wouters BG, Van Schooten FJ, et al. Diminished carcinogen detoxification is a novel mechanism for hypoxia-inducible factor 1-mediated genetic instability. J Biol Chem (2010) 285:14558-64. doi:10.1074/jbc.M109.076323
21. Reddy MV, Randerath K. Nuclease P1-mediated enhancement of sensitivity of 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis (1986) 7:1543-51. doi:10.1093/carcin/7.9.1543
22. Godschalk RW, Maas LM, Van Zandwijk N, Van 't Veer LJ, Breedijk A, Borm PJ, et al. Differences in aromatic-DNA adduct levels between alveolar macrophages and subpopulations of white blood cells from smokers. Carcinogenesis (1998) 19:819-25. doi:10.1093/carcin/19.5.819
23. Langie SA, Knaapen AM, Brauers KJ, Van Berlo D, Van Schooten FJ, Godschalk RW. Development and validation of a modified comet assay to phenotypically assess nucleotide excision repair. Mutagenesis (2006) 21:153-8. doi:10.1093/mutage/gel013
24. Knaapen AM, Schins RP, Borm PJ, Van Schooten FJ. Nitrite enhances neutrophil-induced DNA strand breakage in pulmonary epithelial cells by inhibition of myeloperoxidase. Carcinogenesis (2005) 26:1642-8. doi:10.1093/carcin/bgi116
25. Uppstad H, Ovrebo S, Haugen A, Mollerup S. Importance of CYP1A1 and CYP1B1 in bioactivation of benzo[a]pyrene in human lung cell lines. Toxicol Lett (2010) 192:221-8. doi:10.1016/j.toxlet.2009.10.025
26. Bartsch H, Castegnaro M, Rojas M, Camus AM, Alexandrov K, Lang M. Expression of pulmonary cytochrome P4501A1 and carcinogen DNA adduct formation in high risk subjects for tobacco-related lung cancer. Toxicol Lett (1992) 64-65:477-83. doi:10.1016/0378-4274(92)90222-6
27. Kouri RE, Mckinney CE, Slomiany DJ, Snodgrass DR, Wray NP, Mclemore TL. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res (1982) 42:5030-7.
28. Kiyohara C, Nakanishi Y, Inutsuka S, Takayama K, Hara N, Motohiro A, et al. The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. Pharmacogenetics (1998) 8:315-23. doi:10.1097/00008571-199808000-00005
29. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer (2001) 1:22-33. doi:10.1038/35094000
30. Yuan J, Narayanan L, Rockwell S, Glazer PM. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res (2000) 60:4372-6.